Pediatric MOGAD Treatment: Timing & Variability
Table of Contents
New research highlights variations in treatment strategies for MOG antibody-associated disease (MOGAD) in pediatric patients, with a focus on maintenance therapy decisions and the role of neurofilament light chain.
Understanding MOGAD Treatment Approaches
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune disorder that affects the central nervous system.While advancements in understanding MOGAD are ongoing, clinical practice patterns for managing this condition, particularly in pediatric populations, continue to evolve. A recent study, published in Neurology, sheds light on the diverse approaches taken by neurologists regarding maintenance therapy and diagnostic follow-up for MOGAD.
Maintenance Therapy: A Crucial Decision Point
The decision to initiate maintenance therapy for pediatric MOGAD patients is a critical one, often guided by the occurrence of clinical attacks. The study found a near-universal consensus among respondents regarding the initiation of maintenance therapy after a second clinical attack.
Post-second Attack Consensus: A striking 98.2% of respondents reported initiating maintenance therapy following a second clinical attack in a MOG-IgG antibody-positive pediatric patient. This strong agreement underscores the perceived need for sustained immunosuppression to prevent further relapses.
Preferred Agents: Rituximab emerged as the most frequently utilized agent for maintenance therapy, accounting for 37% of responses. Monthly intravenous immunoglobulin (IVIg) followed closely, with 25.5% of neurologists opting for this treatment.
Treatment Duration: The duration of maintenance therapy varied, with 42.9% of respondents indicating a treatment period of 2 years or less. A significant portion, 35.2%, preferred to continue therapy for longer than 2 years, while 21.7% opted for indefinite maintenance.
Differences in Treatment Strategies: NIs vs. Non-NIs
The study also revealed notable differences in maintenance therapy choices between neurologists identified as “NIs” (likely referring to neurologists with a specific focus or expertise, though not explicitly defined in the provided text) and “non-NIs.”
First Clinical Event: Following a first clinical event, non-NIs predominantly favored rituximab (29.3%), followed by daily low-dose oral prednisolone (23.3%). In contrast, NIs most frequently chose monthly IVIg (47.6%) as their initial maintenance therapy.
Post-Second Attack variations: After a second clinical attack, both groups largely agreed on initiating maintenance therapy (97.8% of non-NIs and 99.1% of nis).However, the preferred agents differed: non-NIs leaned towards rituximab (41.7%), while NIs favored monthly IVIg (50%).
Statistical Meaning: Significant differences were observed in the use of monthly IVIg (55/110 among NIs vs. 32/230 among non-NIs; P < 0.001) and azathioprine (9/110 among NIs vs. 49/230 among non-NIs; P = 0.002) between the two groups, highlighting distinct treatment philosophies.
Diagnostic Follow-Up: Reassessing MOG-IgG
The practice of repeating MOG-IgG antibody testing in follow-up also showed variability among respondents.
Testing Frequency: One-third of respondents (36.1%) chose not to repeat MOG-IgG testing. Another third (35.2%) opted to reassess the antibody levels 6 months after clinical onset, suggesting a cautious approach to monitoring.
Limitations and Future Directions
The study acknowledged several limitations that may impact the generalizability of it’s findings.
Survey Completion Rates: Nearly 39% of respondents did not complete the survey, possibly introducing bias.
Geographic and Expertise Bias: Recruitment through U.S.-based channels may have skewed the sample towards neurologists with neuroimmunology interests and those practicing in the United States.While some international responses were received, broader outreach could have improved global portrayal.
Pediatric Practice Insights: The majority of respondents were adult neurologists, limiting the depth of insights into pediatric practice patterns.
* Survey Design: The streamlined design of the survey may have restricted a more in-depth exploration of the factors influencing decision-making.
The authors, Yeh et al., emphasize the critical need for improved